Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2018

View Archived Issues

The point of disorder

How S. pneumonia PLYs its deadly trade

Phase I/II study of novel CAR T-cell therapy is enrolling patients with leukemia or lymphoma

Patient recruitment ongoing in phase II study of SHR-1210 plus BP-102 and Xelox in mCRC

AbbVie initiates phase I study of SC-011 as single agent and in combination with ABBV-181

Nutlin-based PROTAC knockdowns target protein and upregulate p53, decreasing cancer cell viability

Rat model of heritable pulmonary arterial hypertension created with Bmpr2 missense mutation

Identification of small-molecule RPA inhibitors targeting DNA damage response for cancer treatment

Splice variant in HSD17B13 protects against histological damage in NAFLD patients from South America

Phase I study evaluates mogamulizumab with durvalumab or tremelimumab in advanced solid tumors

Study links receptor mutations, calcium signaling, spinocerebellar ataxias

Toray announces an agreement to develop TRK-880

IMV amends phase Ib/II study to develop DPX-Survivac as monotherapy for recurrent ovarian cancer

U.S. researchers patent ACVR1 inhibitors

Harvard College and Macrolide Pharmaceuticals present new antibacterials

Mochida Pharmaceutical identifies new NTRK1 inhibitors

Horitzonts Tecnologics Hungary Kft synthesizes new compounds for infections

GEn1E Lifesciences enters option agreement to license University of Maryland's MUC-ED peptide

FDA approves Gamifant for primary hemophagocytic lymphohistiocytosis

Sparing the liver with a new strategy to activate TNFRSF10B

Aurigene presents the discovery of novel dual inhibitors of CD73 and A2AR

MM-401 demonstrates robust responses in multiple syngeneic mouse tumor models

biOasis reports data from study examining whole-body distribution of xB3-001

Tremfya receives additional indication approval as first biologic agent for palmoplantar pustulosis

Auris holds pre-IND meeting with FDA for AM-201 to prevent olanzapine-induced weight gain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...